Program - Society of Toxicology

44 th Annual Meeting
and ToxExpo
Program Description
Monday Morning
Monday Morning, March 7
9:30 AM to 11:30 AM
Exhibit Hall A
Monday Morning, March 7
7:30 AM to 3:00 PM
Room 214
UNDERGRADUATE EDUCATION PROGRAM FOR MINORITY
STUDENTS
Chairperson(s): Rosita Proteau, SCMI Chair, Oregon State University,
Corvallis, OR.
Sponsored by:
Education Committee
Education Subcommittee for Minority Initiatives
7:30 AM–8:00 AM Breakfast for Students, Advisors, Peer Mentors,
and SOT Hosts
8:15 AM–9:15 AM Plenary Lecture: Science, Policy, and Regulation
at the White House Office of Information and
Regulatory Affairs, John D. Graham, Office of
Information and Regulatory Affairs, OIRA
9:30 AM–11:30 AM Special Poster Session for Visiting Students
POSTER SESSION FOR VISITING STUDENTS
Chairperson(s): Rosita Proteau, SCMI Chair, Oregon State University,
Corvallis, OR and Javier Avalos, TopTox, Sacramento, CA.
Sponsored by:
Education Committee
Education Subcommittee for Minority Initiatives
This poster session is part of the Undergraduate Education Program for
Minority Students. All are welcome to view the specially selected presentations
which provide an overview of research in toxicology and demonstrate the diversity
within the discipline.
Monday Morning, March 7
9:30 AM to 12:00 NOON
Room RO4
SYMPOSIUM SESSION: THE FUTURE OF MOLECULAR GENETIC
THERAPEUTICS
Chairperson(s): David Monteith, Lilly Research Laboratories, Greenfield, IN
and Vijay Reddy, Lilly Research Laboratories, Greenfield, IN.
MONDAY
11:45 AM–1:00 PM Closing Session
1:00 PM–3:00 PM Evaluation Focus Groups
Monday Morning, March 7
8:30 AM to 9:15 AM
La Louisiane Ballroom
PLENARY LECTURE: SCIENCE, POLICY, AND REGULATION AT
THE WHITE HOUSE OFFICE OF INFORMATION AND
REGULATORY AFFAIRS
Lecturer: John D. Graham, Administrator, Office of Management and Budget,
OIRA.
John D. Graham, PhD, is Administrator of the Office of Information and
Regulatory Affairs within the White House Office of Management and Budget.
As OIRA Administrator, Dr. Graham has pursued an agenda of “smarter regulation.”
This means that the office is neither pro-regulation nor anti-regulation.
OIRA seeks to accelerate the adoption of sensible rules, modify existing rules
to make them more effective and less costly, and rescind outdated rules whose
benefits do not justify their costs. Under Dr. Graham’s leadership, OIRA has
made changes in many areas to increase the reliance on sound science. These
initiatives include government-wide Information Quality Guidelines, guidance
on Peer Review, and a revised circular on Regulatory Analysis for benefits and
costs of regulations. Dr. Graham will talk about these initiatives, other OIRA
activities, and also share with SOT ways in which members of the public can
constructively engage in the process of bringing sound science to the policy
arena.
Endorsed by:
Comparative and Veterinary SS
Regulatory and Safety Evaluation SS*
Student Advisory Committee
During the last decade the decoding of the human genome has provided exciting
possibilities for the treatment of human disease. The promise of gene therapy
and antisense have stirred the imagination to the potential of redirecting
abnormal cellular processes. These therapies provide potential advantages in
specificity to gene targets and selectivity for protein intervention in some
disease targets that are often considered ‘undruggable’ with traditional
chemotherapies. To date, these technologies have provided interesting technologies
as research tools to gain perspective with respect to effects of various
targets; in particular antisense strategies using single-strand and siRNA provide
tools to validate molecular targets in disease pathways. These antisense
approaches utilize different mechanisms (i.e., RISK complex and RNase H) to
reduce a target protein in a manner not achievable with a small molecule
approach. Gene therapy has posed the potential to treat and possibly cure disease
by replacing lost function with the insertion of a normal gene. Currently, there
are numerous antisense and gene therapy clinical candidates in development by
corporate sponsors as well as academic centers and investigators. The selection
of disease candidates and targets is complex. The administration, delivery, cell
permeability, and pharmacokinetic and pharmacodynamic attributes have
played a critical role in the development of these therapies. This symposium will
cover the biologic and safety hurdles these therapies have faced and the solutions
that have been developed to evaluate these molecules in patients. The
symposium will consist of an expert panel of presenters involved in the science
and development issues surrounding molecular genetic therapies.
#13 9:30 THE FUTURE OF MOLECULAR GENETIC
THERAPEUTICS. D. Monteith and V. Reddy. Eli Lilly
and Company, Greenfield, IN.
#14 9:40 GENE THERAPY: A SIMPLE CONCEPT WITH
COMPLEX CHALLENGES. R. M. Lyons. Self-
Employed, Gaithersburg, MD.
up-to-date information at www.toxicology.org 49